TESARO (NASDAQ:TSRO) : Traders are bullish on TESARO (NASDAQ:TSRO) as it has outperformed the S&P 500 by a wide margin of 116.39% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.04%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.43% in the last 1 week, and is up 119.88% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 48.55% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $93.33 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $52.01 and the 200 Day Moving Average price is recorded at $44.49.
The stock has recorded a 20-day Moving Average of 62.77% and the 50-Day Moving Average is 85.51%.
TESARO (NASDAQ:TSRO): On Fridays trading session , Opening price of the stock was $91.9 with an intraday high of $93.33. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $87.7. However, the stock managed to close at $88.7, a loss of 3.55% for the day. On the previous day, the stock had closed at $91.96. The total traded volume of the day was 1,811,923 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged that Hanke Jeffrey H., Officer (Executive Vp, R&D And Cso) of TESARO, Inc., had unloaded 12,500 shares at an average price of $74.02 in a transaction dated on June 30, 2016. The total value of the transaction was worth $925,250.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.